Observe Medical Annual Report for 2022
Oslo, 28 April 2023 – Observe Medical ASA ("the Company" or "Observe Medical") today announces that the Company has published its Annual Report for 2022. The Annual Report was approved by the Board of Directors on 27 April 2023.
“In 2022, Observe Medical explored several paths to broaden our product portfolio and secure production capacity. Throughout the year, we capitalised on several exciting opportunities, and I am grateful to the team at Observe Medical, who have met each opportunity and challenge without hesitation. Looking ahead, our ambition remains unchanged, and we continue to work towards becoming a Nordic medtech company with a global reach and presence,” commented Rune Nystad, CEO of Observe Medical.
The Annual Report for 2022 is attached to this notice and available on the Company’s website under the Investor Relations section. The auditor's report, which is incorporated in the annual report, includes a statutory emphasis of matter relating to the further financing of the Company.
For further information, please contact:
Rune Nystad, CEO Observe Medical
Mobile: +47 916 24 683
E-mail: rune.nystad@observemedical.com
Per Arne Nygård, CFO of Observe Medical
Mobile: +47 411 04 345
E-mail: perarne.nygard@observemedical.com
About Observe Medical
Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics. The Company seeks to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care, in combination with targeted M&A.
The Company is headquartered in Oslo, Norway, with additional offices in Narvik, Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US. In addition, Observe Medical has a direct sale organization in the Nordics and a distributor network internationally.
Further information is available at www.observemedical.com.
[The information is such that Observe Medical ASA is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 19.30 CET at 28 April 2023